There are currently 651 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
NCT05600777
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: Pharmacorp Clinical Trials, Inc., Charleston, South Carolina
Conditions: Refractory Chronic Cough
Register for Updates
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
NCT05375084
Recruiting
This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody, in patients with NSCLC with a KRAS mutation. The study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Medical University of South Carolina (MUSC) - Hollings Cancer Center, Charleston, South Carolina
Conditions: Non Small Cell Lung Cancer, Solid Tumor
Register for Updates
Pembrolizumab Plus Olaparib in LA-HNSCC
NCT05366166
Recruiting
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are drugs that are approved for head and neck cancer treatment. However, FDA has not approved the use of these two drugs together in treating head and neck cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Medical University of South Carolina (MUSC), Charleston, South Carolina
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
Post-stroke Psychosocial Recovery
NCT05380037
Recruiting
Stroke is a neurological injury that adversely impacts psychosocial functioning and quality of life. This may occur due to direct insult to the brain circuits integral to adaptive psychosocial functioning, and/or indirectly via significant disruption to routine motor, sensory and cognitive performance. Yet, few evidence-based interventions exist for addressing the broad disruption to emotional and interpersonal functioning specific to stroke, highlighting a clear unmet need. The investigators pr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina
Conditions: Stroke
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
All
Ages:
21 years and below
Trial Updated:
02/13/2024
Locations: Medical University of South Carolina Children's Hospital, Charleston, South Carolina
Conditions: Rheumatic Joint Disease
Register for Updates
Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder
NCT04293341
Recruiting
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive/... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/12/2024
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina
Conditions: Major Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder and Agoraphobia
Register for Updates
Multicenter Study Into Individualized Scanning for Coronary Artery Disease
NCT04837846
Recruiting
To evaluate intravascular attenuation of the coronary arteries and image quality in an individualized scan and CM injection protocol whereas both scan and injection parameters are tailored to the individual patient in a North American, European and Asian patient population. To evaluate the radiation dose and contrast media dose of this individualized approach for CCTA in an American, European and Chinese patient population. To evaluate the injection parameters required for an average American,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Coronary Artery Disease
Register for Updates
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
NCT06079190
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/12/2024
Locations: GSK Investigational Site, Charleston, South Carolina
Conditions: Alzheimer's Disease
Register for Updates
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/09/2024
Locations: Direct Biologics Investigational Site, Charleston, South Carolina
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
NCT05639556
Recruiting
The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies inclu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Cystic Fibrosis
Register for Updates
Enhancing School-Based Violence Prevention
NCT04087772
Recruiting
The purpose of this study is to compare two versions of Mental Health Enhanced Positive Behavioral Interventions and Supports in reducing aggression in middle school students.
Gender:
All
Ages:
Between 10 years and 105 years
Trial Updated:
02/08/2024
Locations: Name and state withheld to protect anonyminty of study site, Charleston, South Carolina
Conditions: Aggressive Childhood Behavior
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates